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Background: Alternatives to treatment for malaria treatment of travellers are needed in the USA and in Europe for
travellers who return with severe malaria infections. The objective of this study is to show the pharmacokinetic (PK)
profile of intravenous artesunate (AS), which was manufactured under good manufacturing practice (GMP)
conditions, in adults with uncomplicated falciparum malaria in Kenya.
Methods: The PK parameters of intravenous AS manufactured under current cGMP were evaluated after a single
dose of drug at 2.4 mg/kg infused over 2 min in 28 adults with uncomplicated Plasmodium falciparum malaria.
Plasma concentrations of AS and dihydroartemisinin (DHA) were measured using a validated liquid
chromatography–mass spectrometry (LC-MS/MS) methodology. Pharmacokinetic data were analysed with a
compartmental analysis for AS and DHA.
Results: The results suggest there were no drug-related adverse events in any of the patients. After intravenous
infusion, the concentration of the parent drug rapidly declined, and the AS was converted to DHA. AS and DHA
showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively. The high mean peak concentration
(Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL. Significant
variability was noted in the PK profiles of the 28 patients tested. For example, Cmax values of AS were calculated to
range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL. The
mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng·h/mL vs 3,543
ng·h/mL). The DHA/AS ratio observed was 1.94 during the one-day single treatment, and the AUC and half- life
measured for DHA were significantly larger and longer than for AS.
Conclusions: Intravenous AS can provide much higher peak concentrations of AS when compared to
concentrations achieved with oral therapy; this may be crucial for the rapid elimination of parasites in patients with
severe malaria. Given the much longer half-life of DHA compared to the short half-life of AS, DHA also plays a
significant role in treatment of severe malaria.
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Intravenous (IV) artesunate (AS) has been shown to com-
pletely inhibit parasite growth in infected human patients
within two to four hours after dosing, and its active me-
tabolite, dihydroartemisinin (DHA), is the only artemisinin
derivative with activity against all asexual blood stage par-
asites [1]. AS treatment results in rapid parasite and fever
clearance, and these effects have been mostly attributed to
its rapid and extensive hydrolysis to DHA [2-4], the most
active schizonticidal metabolite. In vitro bioassay tests
have shown that the activity of DHA is similar to AS [5]
and three- to five-fold more active than other artemisinin
derivatives [6,7]. AS has been shown to be highly effective
against multidrug-resistant falciparum malaria and for
treatment of severe malaria in Vietnam, Thailand, China,
and Myanmar, however, limited studies have been carried
out in Africa [8]. Currently, there are three recommended
treatments for severe and complicated malaria: AS, arte-
mether (AM) and quinine (or quinidine) [9]. The Chinese
manufacturer (Guilin Pharmaceutical Co Ltd, Shanghai,
China) of the injectable AS that was used in most of the
clinical trial studies recently improved its production
process, with support from Medicine for Malaria Venture
(MMV), and their product has achieved World Health
Organization (WHO) recognition. Intravenous quinine or
quinidine, however, is still used in Europe and the USA as
the main barrier for the use of intravenous AS is the ab-
sence of an approved product that is manufactured under
good manufacturing practices (GMP) and is legally avail-
able in these regions for patient treatment [9].
Following recent clinical studies with severe malaria pa-
tients, IV AS was shown to have the highest success for
treatment of malaria with a low incidence of adverse events
[10-12]. The two largest trials ever conducted for severe
malaria in endemic regions showed that, in both adults
and children, treatment with IV AS yields better outcomes
than treatment with IV quinine. The mortality rate among
quinine-treated patients was shown to be 22 and 10.9% in
the Southeast Asia Quinine Artesunate Malarial Trial
(SEAQUAMAT) and Africa Quinine Artesunate Malarial
Trial (AQUAMAT) studies, respectively, and the mortality
rate among AS-treated patients was shown to be 15 and
8.5%, respectively. When comparing the mortality rates
achieved with treatment of these two drugs, AS reduced
mortality by 35% in the SEAQUAMAT trial and 22.5% in
the AQUAMAT trail. Patients with hyperparasitaemia
(>10% of red blood cells (RBC) experienced a significantly
greater treatment effect after AS treatment than patients
that did not have hyperparasitaemia. IV AS was also shown
to be better tolerated, safer and easier to use than quinine.
The life-saving benefit of AS for treatment of severe malaria
was recognized by the WHO in 2010, and since then IVAS
has been the initial treatment of choice for patients with
severe falciparum malaria infections [11,12].Alternatives to treatment for severe malaria are needed
in the USA and Europe for treatment of severe malaria.
While nations in the Third World can choose to use AS
preparations such as the Guilin AS product for treatment
of disease, there are issues with the use of this AS product
in First World countries where the Guilin AS formulation
cannot be sold legally. The objective of this study is to show
the pharmacokinetic (PK) profile of IV AS in Kenyans in-
fected with uncomplicated falciparum malaria. The PK esti-
mates will be also used to compare with the PK profiles
observed in populations of healthy adults administered AS
in another manuscript. The overall goal in the present
study was to provide a well-validated, efficacious, and safe
product for the treatment of severe malaria licensed by the
US Food and Drug Administration (FDA) available for use




The bulk artesunic acid (4-(10’dihydro-artemisinin-oxy-
methyl) succinate) substance was purchased from Knoll
AG (Switzerland). BASF Pharmaceuticals rebottled it from
the original company under GMP conditions. The clinical
trial AS (Batch #: 14462–16) was tested for sterility and
short-term stability. The formulation was contained in
sterilized bottles with 110 mg artesunic acid per bottle.
The injection buffer for AS was manufactured as a GMP
phosphate salt with 0.3 M PBS (pH 8.0). The product was
prepared for administration by reconstitution in sodium
phosphate buffer prior to infusion, which took place
within 1 hr after solution was prepared due to a precipita-
tion in 3–4 hours at room temperature.
Subject background
All subjects gave written informed consent prior to the
commencement of any study procedure (e.g, blood smear).
Overall, 30 adult subjects were enrolled, 20 males and ten
non-pregnant females, aged 18–65 years, with uncompli-
cated Plasmodium falciparum malaria and body weights of
42–85 kg. The subjects of this study resided in a malaria-
endemic region of Kenya and in districts surrounding the
Province of Nyanza. The majority of the population in these
areas is considered semi-immune, however, malaria attack
rates in the city are low, and many adults in this area may
well have waning immunity. The prevalence of malaria in
Nyanza Province has been shown to range from 25 to 45%.
Adult subjects were recruited with signs and symp-
toms of malaria who were seen at the Nyanza Medical
Centre, Kisumu or one of its neighbouring health clinics
(Kisumu District Hospital in Kisumu; Nyahera Health
Centre, Rabuor Dispensary, in Kisumu, and Kombewa
Subdistrict Hospital), Nyanza Province. Local clinicians
made a provisional clinical diagnosis of malaria, and
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laboratory for microscopic examination of blood smears
or rapid malaria antigen tests. Those subjects from the
hospital laboratory who had not initiated therapy after a
positive test were recruited for this study.
The screening process for subject participation consisted
of questionnaires and clinical examinations including
medical history, physical examination, and laboratory ana-
lyses. Phlebotomy was performed to obtain samples for la-
boratory testing and malaria blood films. A clean-catch
urine specimen was also collected for urinalysis and preg-
nancy testing, as applicable. Baseline safety testing in-
cluded both clinical chemistry and haematology testing.
Analyses included blood urea nitrogen (BUN), creatinine,
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), total and direct bilirubin, reticulocyte, and a
complete blood cell (CBC) count with differential as-
sessment. Ultimately, enrolment determinations con-
sisted of compliance with inclusion and exclusion
criteria, including a diagnosis of uncomplicated P. fal-
ciparum malaria with at least 200 parasites per μL con-
firmed by malaria blood smear.
Study design
This was a Phase II, open-label, non-randomized PK
clinical trial of IV AS. Subjects completed an outpatient
visit at the study centre for confirmation of study eligi-
bility and baseline electrocardiogram monitoring. All
subjects received an identical dose of the test article: in-
jectable IV AS daily for two days consisting of 2.4 mg/kg
delivered over 2 min. Safety, PK and efficacy assessments
occurred intermittently with follow-on standard therapy
with a three-day course of Malarone® to ensure cure.
After completion of each injection, the study nurse ex-
amined how well AS injection was tolerated by perform-
ing inspection of the injection site and subject response.
Normal activities, excluding strenuous exercise, were
permitted four hours after dosing. The clinical trial iden-
tifier in ClinicalTrials.gov is NCT00298610 [13]. The hu-
man use protocol numbers for this Phase II trial are
Uniformed Services University of the Health Sciences
(USUHS) #G183RW; Walter Reed Army Institute of
Research (WRIAR) #1128; Human Subjects Research
Review Board (HSRRB) #A13331, and the Kenya Medical
Research Institute (KEMRI) #917.
PK and finger-stick sampling
PK sampling was performed using a flush saline technique
from an IV line or phlebotomy if the IV line was compro-
mised. Samples were collected on day 1 approximately 10
min before dosing (0 hours), and at the following nominal
time points after dosing: 5, 10, 20, and 40 min, and 1, 2, 4,
and 6 hours. The blood (6 ml) will be collected from each
subject via a cannula or by repeated venipuncture(opposite arm from infusion) into lithium heparin tubes.
Actual time points were obtained within ± 20% of the stated
time points, and the plasma samples were immediately
stored at approximately −70°C after collection, and shipped
to the Armed Forces Research Institute of Medical Sciences
(AFRIMS) Bangkok, Thailand on dry ice, for analysis.
Finger-stick sampling was used for any malaria blood films
collected at time points not requiring phlebotomy.
Treatment and monitoring
Subjects were treated and monitored as outpatients or
inpatients as deemed necessary by the subject, study
staff and the principal investigator. Subjects managed as
outpatients were permitted to leave the study site after the
first dose of study drug (day 0) and sampling (approxi-
mately eight hours). Subjects were required to return the
following day for scheduled follow-up.
LC-MS assay
An LC-MS method for the quantitation of AS and DHA
(100 μL) in human plasma was validated in a range from
1.4-1,153 ng/mL for AS and from 1.1-853 ng/mL for
DHA. The analytes were extracted from human plasma
after protein precipitation using two volumes of ice-cold
acetonitrile. After centrifugation at 10,000 rpm, the clear
supernatant extracts were analysed on a single quadru-
pole Mass Spectrometer (Micromass ZQ, MM1, Waters
Corp, Milford, MA, USA) in the positive ion electrospray
ionization (+ESI) mode. The AS and DHA compounds
were monitored using single ion recording. The LC-MS
with a reversed phase column (XTerra MS C18, 3.5 μm,
2.1 × 50 mm) and a pre-column of the same material
(2.1 × 10 mm) was mounted on a liquid chromatography
system (Alliance 2695, Waters Corp, Milford, MA, USA).
The method was performed a gradient elution with the
following mobile phases: A) 6.25 mM ammonium acetate
in water (pH 4.5) and B) 100% acetonitrile gradient from
20 to 40% in ammonium acetate buffer in 9 min at the
flow rate of 0.4 mL/min. The ammonium-adducts of
DHA were detected at a mass to charge ratio (m/z) of 302
and eluted in 5 min, while adducts of AS were detected at
a mass to charge ratio of 402 and eluted in 6 min. The
total analysis time for both compounds was 12 min.
In these methods, the intra-assay and inter-assay accur-
acy and precision (n = 6) had an inaccuracy rate of ± 8.4%
and coefficient of variations (CVs) of ≤7.9% at 19.2/14.2
(50), 192/142 (500), 961/711 (2,500) and 1,153/853 (3,000)
ng/mL (nM) for AS/DHA. The intra-assay and inter-assay
inaccuracy and precision were within ± 6.0 and ≤17.6%, re-
spectively [14]. Standard curve and quality control (QC)
samples were generated by spiking interference-free human
plasma samples with known amounts of AS, DHA and in-
ternal standard. The drug concentrations of the QC sam-
ples chosen were within the range of the standard curve,
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levels. The lower limit of quantitation (LLOQ) was 1.44/
1.07 (3.75) ng/mL (nM) for AS/DHA. Any out-of-trend
concentration values were re-analysed with the average of
three repeated values used in PK parameter determination.
Calibration standards and QC samples were analysed to
evaluate the performance of the assay and were the same
as the validated method previously described [14].Pharmacokinetic analysis
In order to compare only the clinically relevant AS con-
centrations, a compartmental PK analysis was based on a
short-term (2 min) IV infusion on individual patient level
in accordance with a previous PK evaluation [15,16]. The
disposition of injectable AS was best described by a two-
compartment model with a rapid initial distribution phase
after IV administration. The input of the drug was as-
sumed to follow zero-order kinetics, and elimination from
the central compartment occurred with first-order kinet-
ics. compartmental analysis (CA) of concentration-time data
for AS was performed by using the Phoenix-WinNonlin
software Version 6.3 (Pharsight Corp, Mountain View,
CA, USA) with an IV infusion programme. The first-
order method with logarithmic transformation of all drug-
concentration data was used throughout.
The drug plasma concentrations at the end of IV infusion
(Cmax) were calculated from the corresponding model
equations (IV-infusion model, WinNonlin) at the respective
time points. The AUCinf was estimated by direct integration
of equation with CA modeling from zero to infinity. The
total clearance (CL) is calculated with dose divided by total
AUC. The Cmax and the time to maximum drug concentra-
tion (Tmax) were obtained from the PK modeling. The pre-
dicted AS concentration at the end of the infusion (2 min),
however, was calculated by compartmental modelling. The
values of the following PK parameters were derived by a
compartmental method. The elimination half-life (t½),
mean residence time (MRT), the AUC from time zero to
the last sampling time (AUCt), the AUC from time zero ex-
trapolated to infinity (AUCinf), total systemic clearance
(CL), and the volume of distribution during steady state
(Vss) were obtained by PK modeling.
Previous PK analysis [15] and PK estimates in the present
study confirmed that the PK parameters of DHA are similar
when using the non-compartmental analysis (NCA) and CA
analyses, suggesting that PK modelling of DHA is model-
independent. Thus, the both methods are suitable for DHA.
The values of the following PK parameters were derived by a
compartmental method with the Cmax, t½, MRT, AUCinf,
relative total systemic clearance (CL/F), and the volume
of distribution during steady state (Vss/F). The AUCinf ratios
of AS to its metabolite (DHA) were calculated to determine
exposure to any metabolite compared with the parent drug.Results
IV AS manufactured to be cGMP compliant was admin-
istrated to 30 adult patients. PK samples were not col-
lected for two subjects (Two cases have been excluded
due to the insufficient data). Efficacy and safety evalua-
tions will be discussed in detail in a separate manuscript.
Safety and tolerability
In this study, 30 patients with uncomplicated P. falcip-
arum malaria were treated with an intravenous infusion
of AS (2.4 mg/kg given over 2 min) daily for two days.
For each subject, adverse events (AEs) were recorded
throughout the post-dosing period. Multiple doses of
this formulation of AS administered intravenously at a
dose of 2.4 mg/kg daily for two consecutive days were
well tolerated in all patients. No dose related toxicity
was found for AS at the doses studied. There were no
subject dropouts for AEs or other treatment-related issues.
The dose-related decrease in reticulocyte count was noted
that reached its lowest point four days after dosing and
returned to normal by study day 7 in most cases. There
were no other clinically significant laboratory abnormalities
detected. No deleterious haemodynamic or electrocardiog-
raphy (ECG) effects were seen. A transient, reversible sen-
sation of altered or unusual taste, which lasted less than 30
min in all cases, was associated with intravenous dosing of
AS. All remaining side effects were generally mild and all
were reversible.
Pharmacokinetics of AS and DHA
PK evaluations of AS for the 28 subjects in this study
were completed using compartmental model analysis. The
compartmental PK analysis performed resulted in a two-
compartment model of IV infusion with first-order elimin-
ation, which best fit the set of observations [15,16]. The
plasma AS concentration and the final PK parameter esti-
mates for AS after IV infusion of 2.4 mg/kg AS based on a
two-compartment model are shown in Figure 1 and
Table 1, respectively. After the short-term infusion of AS
(0.028 hours), the mean Cmax of AS was shown to be
28,558 ng/mL at the ending time of the infusion for the
study population. The comparison results support the sug-
gestion that PK analysis of AS may be performed only
with compartment modelling [15]. After the injection of
2.4 mg/kg of AS, the mean AUC obtained with this dose
was 1,878 ng∙h/mL. The elimination half-life for AS was
ranged from 0.09 to 0.25 hours with a mean elimination
half-life of 0.17 hours. The MRT of AS was shown to be
only 0.07 hours following AS infusion. The CL and Vss
were calculated to be 1,728 mL/h/kg and 139 mL/kg,
respectively (Table 1).
The plasma concentrations of DHA after short-term in-
fusion of a single dose of 2.4 mg/kg are shown in Figure 2.
Table 1 shows the mean parameters derived in a first
Figure 1 Concentration-time profile of artesunate (AS) in
plasma measured by LC-MS (empty diamond) and mean
concentration curve (solid-line) fitted by the compartment
analysis with intravenous infusion model following 0.028 hr
intravenous infusion (2 minutes) with cGMP injection AS at
dose of 2.4 mg/kg in adult patients with uncomplicated
falciparum malaria (n = 28).
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AUCinf for DHA were shown to be 2,932 ng·/mL and 3,543
ng · h/mL, respectively, in the AS-treated patients. The
mean Tmax was shown to range from 0.12 - 0.28 hours, and
the mean elimination t½ was shown to be 1.30 hours. The
CL/F and Vss/F were shown to be 731 mL/h/kg and 1,048
mL/kg, respectively.
Variable PK profiles of AS and DHA
In the 28 malaria patients evaluated in this study, the
peak concentrations (Cmax) of AS following IV infusion
ranged from 3,362 to 55,873 ng/mL, and the AUC of AS
ranged from 477 to 6,434 ng · h/mL, suggesting a largeTable 1 Mean pharmacokinetic parameters of artesunate (AS)
pharmacokinetic modelling by using compartment analysis w
infusion (2 minutes) at single dose of 2.4 mg/kg in the adults
PK parameters artesunate CA IV-infusion (PK model 9) CV (%) PK p
Cmax (ng/mL) 28,558 ± 28,531 99.8
Tmax (h) 0.028 ± 0.015 54.6
AUCinf (ng · h/mL) 1,879 ± 1,190 63.4
t1/2 distribution (h) 0.05 ± 0.01 15.2
t1/2 elimination (h) 0.17 ± 0.08 47.4
CL (mL/h/kg) 1,728 ± 983 56.9
Vss (mL/kg) 139 ± 124 89.2
MRT (h) 0.07 ± 0.02 30.9
Ratio of AUCDHA/AS
Ratio of Cmax AS/DHA
Ratio of t1/2 DHA/AS
Data are presented as arithmetic mean (CV%); CA = compartment analysis (Phoenix-Wi
for DHA); F = bioavailability; MRT=mean residence time.inter-individual variability in these PK parameters. Simi-
larly, the Cmax of DHA ranged from 1,493 to 5,569 ng/mL,
and the AUC values calculated ranged from 2,024 to 5,424
ng · h/mL.
The concentration of DHA, which was converted from
AS, was also shown to be highly variable in the 28 pa-
tients evaluated. The ratio of AUCDHA/AS ranged from
0.72 to 4.16 (Table 1). In addition, the AUC of DHA was
significantly higher than the AUC of AS with a mean
AUCDHA/AS ratio of 1.94, however, the peak concentra-
tion of AS was much higher than that of DHA with a
mean Cmax AS/DHA ratio of 10.24. DHA was also shown
to have a 7.65-fold longer elimination half-life than AS.
Discussion
IV AS has been used to treat patients with both uncom-
plicated P. falciparum and severe malaria for more than
25 years [11]. Artesunate has been shown to be highly
effective against multidrug resistant falciparum malaria
and for treatment of severe malaria in Asia. However, the
main barrier for the use of intravenous AS in Western
countries is the absence of an approved product manufac-
tured under GMP. A major concern that has been
expressed is that the currently available AS products avail-
able for use are not available in Western countries for
treatment of travellers with severe malaria because they
are not licensed for use in either Europe or the USA.
While there is no evidence in clinical trials conducted to
date that the absence of GMP-produced AS translates into
reduced efficacy, there are significant long-term benefits to
patient care associated with implementing a licensed GMP
artesunate product that is available for treatment of travel-
lers with severe malaria who cannot be given an unlicensed
product. GMP AS is currently under development, bothand its active metabolite dihydroartemisinin (DHA) after
ith IV-infusion fitting for AS following single intravenous
with uncomplicated falciparum malaria in Kenya (n = 28)
arameters dihydroartemisinin CA analysis (PK model 14) CV (%)
Cmax (ng/mL) 2,932 ± 850 28.9
Tmax (h) 0.18 ± 0.06 30.0
AUCinf (ng · h/mL) 3,543 ± 989 27.9
t1/2 distribution (h) 0.13 ± 0.05 38.5
t1/2 elimination (h) 1.30 ± 0.34 26.5
CL/F (mL/h/kg) 731 ± 205 28.0
Vss/F (mL/kg) 1,048 ± 250 23.8
MRT (h) 1.61 ± 0.44 27.3
1.94 ± 1.16 59.8
10.24 ± 7.61 74.3
7.65 ± 3.16 41.3
nNonlin Version 6.3 with compartment model 9, IV-infusion for AS and model 14
Figure 2 Concentration-time profile of dihydroartemisinin
(DHA) in plasma measured by LC-MS (empty cycle) and mean
concentration curve (solid-line) fitted by the compartment
analysis following single intravenous infusion with cGMP
injection AS at dose of 2.4 mg/kg in adult patients with
uncomplicated falciparum malaria (n = 28).
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malaria [17].
The two available methods used for determining PK pa-
rameters of AS and DHA are the compartmental (model-
dependent) and non-compartment (model-independent)
PK analytical techniques [18]. PK evaluation of IV AS with
a short-term IV infusion, however, requires compartmen-
tal analysis. When using NCA for AS PK parameter mod-
elling, the AUC calculation for AS will be adversely
perturbed due to the loss of accurate assessment of Cmax
at the end of the 2-min IV infusion. In previous published
reports, the AUC of AS calculated using NCA underesti-
mated the AUC parameter by 28-49% when compared to
CA analysis [15,16]. Similar underestimation of AUC was
also shown in this study. Therefore, the CA analysis model
is capable of accurately determining the PK parameters of
both AS and DHA in this study. For further evaluation of
PK modeling of intravenous AS administered by infusion,
a specific manuscript is being prepared based on the PK
data from three clinical trials utilizing a variety of PK soft-
ware packages.
In this study and as previously reported, artesunate is
rapidly converted to DHA [9]. DHA was detected in all
patients’ plasma up to six hours after administration, while
the parent drug (AS) was undetectable at time-points as
early as one to two hours after each short-term infusion.
Although the plasma exposure of DHA was increased
when compared to AS with an AUCDHA/AS ratio of 1.94,
the peak concentration of AS was shown to be much
higher than DHA with a Cmax AS/Cmax DHA ratio of 10.24.
In this study, DHA was shown to have 7.65-fold longer
half-life than that of AS. Therefore, the efficacy of AS
has been attributed both to its own intrinsic activity and
to the activity of its principle metabolite, DHA [2-4].The high peak concentrations achieved after dosing pa-
tients intravenously with AS provides a significant advan-
tage over other anti-malarial drugs to achieve rapid killing
of malaria parasites. A number of pharmacokinetic and
pharmacodynamic evaluations have shown that the rapid
efficacy of artemisinins is principally due to the elevated
Cmax achieved after drug administration, and further stud-
ies have shown that AS is superior to other artemisinin
analogues in terms of the very high Cmax observed follow-
ing oral or IV administration [19]. Other PK parameters,
such as the drug exposure level (AUC), and drug exposure
time (half-life) have been shown to be of lesser importance
[19,20]. A number of studies have also shown the rapid
pharmacodynamic effects of these drugs in rapidly de-
creasing the parasite biomass after administration [21].
Significant inter-individual variability in AS PK parame-
ters was shown in this study with coefficients of variation
(CV) of 47.4-99.8% (Table 1), which is much higher than
the CVs observed for DHA, which ranged from 23.8-
38.5%. One particular patient in previous study showed
the highest peak concentration of AS at 55,873 ng/mL,
which was 16.6-fold more than the patient with the lowest
AS concentration (3,362 ng/mL). The currently used
therapeutic doses of injectable AS administered for treat-
ment of severe and complicated malaria are in the range
of 2–2.4 mg/kg. This regimen will produce a Cmax of AS
ranging from 130–16,149 ng/mL in adult patients, demon-
strating the significant variability (about 124-fold between
different trials) following intravenous AS administration
(Table 2, Refs. [22-28]). One could speculate that the sub-
stantial variability is a function of imprecision around the
duration of the infusion dose, the relative imprecision
around the plasma sampling, the rate of AS converted to
DHA, and various other individual patient factors.
The dose of intravenous AS currently used for clinical
use was designed in accordance with prior experience
of physicians over the last 25 years who were concerned
with neurotoxicity and dose-dependent haemotoxicity and
thus, the dose was limited to 2–2.4 mg/kg to prevent a
submaximal anti-malarial effect, and to sustain a mini-
mum curative rate >90% [29]. The lower peak concentra-
tions achieved in some patients, however, especially those
who have severe and complicated malaria associated with
hyperparasitaemia of >5% may result in clinical failure. In
the SEAQUAMAT and AQUAMAT clinical trial studies,
IV AS was shown to be superior to quinine, and patients
with hyperparasitaemia had a significantly greater treat-
ment response to AS than in patients without hyperparasi-
taemia [9-12].
In theory, patients with severe malaria require a peak
concentration of AS ranging from 7,500-30,000 ng/mL to
efficaciously exterminate malaria parasites where parasit-
aemia exceeds 5% [30]. This calculation is based on the
drug concentration achieved at equilibrium after oral AS
Table 2 The main pharmacokinetic parameters of artesunate (AS) and dihydroartemisinin (DHA) following intravenous (IV) administrations in malaria patients
and volunteers
Artesunate (AS) Dihydroartemisinin (DHA) Ratio of
AUCDHA/AS
Refs
Patients Where Cases Date Route Dose Cmax ng/mL AUC ng · h/mL t1/2 min Cmax ng/mL AUC ng · h/mL t1/2 min
Children Gabon 10 2002 IV 2.4 mg/kg 29,683 3,752 1.5 3,012 3,325 20.7 0.89 [22]
Children Ghana 9 2001 IV 2.4 mg/kg 1,593 1,708 31.8 - [23]
Adults Vietnam 13 1998 IV 120 mg/person 11,343 1,146 2.7 2,646 2,378 40.2 2.08 [24]
Adults Vietnam 11 2002 IV 120 mg/person 16,149 1,038 3.2 2,760 2,873 59.0 2.77 [25]
Adults Thailand 2 2000 IV 2 mg/kg - 1,056 - 3,999 - 3.79 [26]
Adults Vietnam 12 1998 IV 120 mg/person 13,688 877 2.2 2,193 1,846 36.7 2.10 [2]
Volunteer Vietnam 10 2001 IV 120 mg/person - 846 2.6 1,508 1,365 53.0 1.61 [27]
Adults Vietnam 8 2001 IV 120 mg/person - - 2.3 2,423 2,081 40.0 - [3]
Adults Vietnam 6 2001 IV 120 mg/person - - 4.3 2,537 2,565 64.1 - [28]
Adults Vietnam 10 2001 IV 240 mg/person - - 3.2 912 5,586 46.2 - [27]
Adults Thailand 17 2006 IV 2.4 mg/kg 130 49 13.2 605 418 20.4 8.53 [28]
Volunteer USA 6 2009 IV 2 mg/kg 19,420 1,595 14.4 1,456 1,821 78.6 1.14 [15]
Volunteer USA 6 2012 IV 2 mg/kg 28,411 2,051 9.6 1,735 2,121 104.4 1.03 [16]
Adults Kenya 28 2014 IV 2.4 mg/kg 28,558 1,878 10.2 2,932 3,543 78.0 1.94 Present
The drug measurements are by using HPLC-ECD or LC-MS methods, and some drug evaluations by using bioassay are not selected in this summary.
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http://www.malariajournal.com/content/13/1/281administration of 1,250 ng/mL (AS plus DHA), which
was required to cure patients infected with malaria
who had a parasitaemia of 1%. The estimation of pa-
tients with severe malaria would require a peak plasma
concentration of AS plus DHA at least 7,500 ng/mL
to effectively reduce the parasite biomass in patients with
severe malaria given previous data and the data from
other trials. Accordingly, dosing of AS at 2.0 - 2.4 mg/kg
intravenously will likely not satisfactorily distribute an
efficacious drug level to every erythrocyte (infected and
uninfected) in each patient with hyperparasitaemia. When
taking into account the large variability in PK and PD bet-
ween individuals, a larger dose will be required to ensure
that a maximum effect is obtained in all patients. The
patients with hyperparasitaemia are effectively treated
is to increase the intravenous loading dose to a higher
level in the range of 4–8 mg/kg, which should be well
tolerated given other studies showing single and mul-
tiple injections of AS in volunteers up to a dose of 8
mg/kg dose were exceedingly well tolerated [15,16].
However, further trials are needed to test this dose
and the frequency of IV AS treatments at that dose re-
quired to achieve cures of patients with severe malaria
patients.
Conclusion
The study presented here underlines the need for appro-
priate PK analysis of AS and DHA following intravenous
infusion. Injectable AS is a superior anti-malarial agent
yielding very high peak plasma concentrations over a
very short exposure time. The higher peak level serves
to eliminate parasites rapidly, and the short exposure
time aids in avoiding fatal neurotoxicity [31]. Previous
data from other studies have shown that administra-
tion of injectable AS at doses up to 8 mg/kg is safe
[15,16], and given the large inter-individual variability as-
sociated with AS administration, use of higher doses may
increase the probability of success in patients with hyper-
parasitaemia associated with severe malaria [20,32].Competing interests
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